The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge

After gaining experience conducting both auto and allografts in persons with hematological diseases in the HSCT programs in Puebla and Monterrey, México, this study outlines subsequent program autografting patients with autoimmune conditions. The first transplant in multiple sclerosis was conducted in Puebla on July 5, 2006. From 2015 we increased activity autografting persons with autoimmune conditions in the two campuses of the HSCT-México program: Puebla and Monterrey. By December 6, 2020, patient number 1,000 in the program was autografted. In our experience, a significant reduction in the expanded disability status scale score was achieved in all of the three phenotypes of the disease (from a median of 5.1 to 4.5 points), whereas the response rate (defined as a decrease of at least 0.5 of EDSS score regardless of baseline EDSS, or unchanged EDSS) was 83, 78, and 73% after 12 months in the relapsing-remitting, primary-progressive and secondary-progressive forms of multiple sclerosis, respectively. In addition to analyzing the viability, safety, and efficacy of our method, this study contributes new knowledge to the field of both stem cell transplantation and multiple sclerosis.

[1]  Carmina Alejandra Córdova-Ramírez,et al.  Early Response Predicts Long-Term Improvement or Stabilization of Persons with Multiple Sclerosis Treated with Hematopoietic Stem Cell Transplantation , 2020 .

[2]  G. Ruiz-Argüelles Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting. , 2020, The Lancet Haematology.

[3]  D. Cilloni,et al.  Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients , 2020, Neurology and Therapy.

[4]  D. Gómez-Almaguer,et al.  Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant. , 2020, Cytotherapy.

[5]  R. Gale,et al.  Mélange intéressante: COVID-19, autologous transplants and multiple sclerosis , 2020, Hematology.

[6]  G. Ruiz-Argüelles,et al.  Respiratory impairment in persons with multiple sclerosis: A cross-sectional study , 2019 .

[7]  G. Ruiz-Argüelles,et al.  Self‐reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real‐world data from a single center , 2019, Clinical and experimental immunology.

[8]  D. Fedorenko,et al.  Long-term outcomes of nonmyeloablative autologous hematopoietic stem cell transplantation in multiple sclerosis , 2019, Journal of the Neurological Sciences.

[9]  R. Gale,et al.  Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non‐frozen grafts in persons with multiple sclerosis , 2019, Clinical transplantation.

[10]  Jeffrey A. Cohen,et al.  Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  B. Sharrack,et al.  Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial , 2019, JAMA.

[12]  G. Ruiz-Argüelles,et al.  Metabolomic profile of insulin resistance in patients with multiple sclerosis is associated to the severity of the disease. , 2018, Multiple sclerosis and related disorders.

[13]  G. Ruiz-Argüelles,et al.  Glomerular Filtration Rate in Patients with Multiple Sclerosis Undergoing Stem Cell Transplantation and Treated with Cyclophosphamide , 2018, Laboratory medicine.

[14]  R. Gale,et al.  Autotransplantations Without Cryopreservation , 2018, Journal of global oncology.

[15]  J. Szer,et al.  Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs? , 2017, Biology of Blood and Marrow Transplantation.

[16]  G. Ruiz-Argüelles,et al.  Hematopoietic stem cell transplants for persons with multiple sclerosis: Is this the best therapeutic option? , 2017 .

[17]  M. Sormani,et al.  Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis , 2017, Nature Reviews Neurology.

[18]  H. Atkins,et al.  Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis , 2017, JAMA neurology.

[19]  D. Arnold,et al.  High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS , 2017, Neurology.

[20]  G. Ruiz-Argüelles,et al.  A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells , 2016, Acta Haematologica.

[21]  G. Ruiz-Argüelles,et al.  Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation. , 2016, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[22]  J. Johansson,et al.  Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  Pedagógia,et al.  Cross Sectional Study , 2019 .

[24]  B. Xu,et al.  Treatment of mild–moderate calcified coronary lesions with sirolimus-eluting stent: real world data from a single center , 2010, Coronary artery disease.

[25]  P. Madden The Swedish experience. , 1988, The Health service journal.

[26]  J. Gottdiener,et al.  Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.